Evidence map›Paper›PMID 35037144›Full record

ReviewMolecular and cellular biochemistry2022

The role of T-LAK cell-originated protein kinase in targeted cancer therapy.

Lu Zhang, Fei Wang, Huijun Yi, Svetlana P Ermakova, Olesya S Malyarenko, Jianmei Mo, Yingze Huang, Qiuhong Duan, Juanjuan Xiao, Feng Zhu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular and cellular biochemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. TOPK Suppresses the CD8Cancer communications (London, England) · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Lu ZhangDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, People's Republic of China.
Fei WangDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, People's Republic of China.
Huijun YiCancer Research Institute, The Affiliated Hospital of Guilin Medical University, Guilin, 541000, Guangxi, China.
Svetlana P ErmakovaLaboratory of Enzyme Chemistry, Far Eastern Branch of Russian Academy of Sciences, G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Vladivostok, Russian Federation, 690022.
Olesya S MalyarenkoLaboratory of Enzyme Chemistry, Far Eastern Branch of Russian Academy of Sciences, G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Vladivostok, Russian Federation, 690022.
Jianmei MoCancer Research Institute, The Affiliated Hospital of Guilin Medical University, Guilin, 541000, Guangxi, China.
Yingze HuangCancer Research Institute, The Affiliated Hospital of Guilin Medical University, Guilin, 541000, Guangxi, China.
Qiuhong DuanDepartment of Biochemistry and Molecular Biology, School of Basic Medicine, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, People's Republic of China. duanqhwz@hust.edu.cn.
Juanjuan XiaoCancer Research Institute, The Affiliated Hospital of Guilin Medical University, Guilin, 541000, Guangxi, China. xjjuan2006@glmc.edu.cn.
Feng ZhuCancer Research Institute, The Affiliated Hospital of Guilin Medical University, Guilin, 541000, Guangxi, China. fengzhu@glmc.edu.cn.ORCID http://orcid.org/0000-0001-9852-0925
Guilin Medical University · CNHuazhong University of Science and Technology · CNPacific Institute of Bioorganic Chemistry. GB Elyakova Far Eastern Branch of the Russian Academy of Sciences · RU

Funding

Health and Family Planning Commission of Hubei Province WJ2019M109National Natural Science Foundation of China 81672739National Natural Science Foundation of China 81672936National Natural Science Foundation of China 81972762Science and Technology Department of Guangxi Zhuang Autonomous Guike AD20297047Young Scientists Fund 81902849
6 · The paper itself

Abstract

Targeted therapy has gradually become the first-line clinical tumor therapy due to its high specificity and low rate of side effects. TOPK (T-LAK cell-originated protein kinase), a MAP kinase, is highly expressed in various tumor tissues, while it is rarely expressed in normal tissues, with the exceptions of testicular germ cells and some fetal tissues. It can promote cancer cell proliferation and migration and is also related to drug resistance. Therefore, TOPK is considered a good therapeutic target. Moreover, a number of studies have shown that targeting TOPK can inhibit the proliferation of cancer cells and promote their apoptosis. Here, we discussed the biological functions of TOPK in cancer and summarized its tumor-related signaling network and known TOPK inhibitors. Finally, the role of TOPK in targeted cancer therapy was concluded, and future research directions for TOPK were assessed.

Indexed as

Drug Delivery SystemsMitogen-Activated Protein Kinase KinasesNeoplasm ProteinsNeoplasmsAnimalsApoptosisCell ProliferationHumansProtein Kinase InhibitorsSignal TransductionMitogen-Activated Protein Kinase KinasesNeoplasm ProteinsPDZ-binding kinaseProtein Kinase InhibitorsCancer resistancePathwayTargeted therapyTOPKTumor metastasis

Identifiers

PMID35037144
OpenAlexW4206144617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.